Answers are grounded in this paper and cite their sources.
Aim The aim of this study was to evaluate the safety and efficacy of low-dose (0.01%) topical atropine eye drops for slowing down the progression of myopia in children and adolescents. Patients and methods A total of 600 eyes of 300 patients aged from 8 to 14 years were included in the study. They were divided into two groups: group A, which included 300 myopic eyes with a spherical equivalent (SE) between −3.00 and −6.00 D that received low-dose (0.01%) topical atropine eye drops once daily for 1 year, and group B as a control group, which consisted of 300 myopic eyes (with SE between −3.00 and −6.00 D) that did not receive the topical atropine eye drops. Posttherapy follow-up for myopia progression was done at 6 months, 1, 1.5, 2, 2.5, and 3 years. Results By the end of 3 years, the mean SE was −5.1±1.75 D in group A in comparison with −6.15±3.15 D in group B. The progression of myopia was significantly more in group B than in group A after 1 year of follow-up and continued with statistically significant difference till the end of the follow-up period. No significant changes in topography or pachymetry were reported in the present study. In addition, no complications related to the low-dose topical atropine drops (0.01%) were reported. Conclusion The use of low-dose (0.01%) topical atropine eye drops was safe and effective in decreasing the progression of myopia in children and adolescents.
No takes yet. Share an insight, caveat, or question.
Alhagaa et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: